Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Life Insurance stock receives double upgrade on Q2 beat and improved outlook

EditorAhmed Abdulazez Abdulkadir
Published 11/12/2024, 04:52 AM
LIFI
-

On Tuesday, JPMorgan upgraded shares of Life Insurance (NS:LIFI) Corporation (LICI:IN), changing its rating from Underweight to Overweight. The firm also increased the price target to INR1,075.00 from the previous INR790.00. The upgrade follows a robust second-quarter performance by the insurer, with the value of new business (VNB) surging by 47% year-over-year to Rs29.4 billion. This figure surpassed JPMorgan's estimate of Rs21.1 billion.

The substantial growth in VNB was attributed to a 26% year-over-year increase in Annual Premium Equivalent (APE) and a significant margin expansion of 2.6 percentage points year-over-year to 17.9%. Analysts noted the margin improvement was particularly driven by a favorable product mix, with a larger contribution from individual non-participating product APE, which constituted 19% in the second quarter of 2025 compared to 7% in the same quarter the previous year.

Life Insurance Corporation's stock had experienced a 22% decline over the last three months, underperforming the Nifty index, which saw a 2% decrease. JPMorgan's previous Underweight thesis was based on expectations of margin pressure from increased product benefits, but the recent results indicate that this concern has largely been realized. The firm now believes that Life Insurance Corporation's commitment to enhancing its product mix is likely to be sustained and will continue to mitigate the potential negative effects of higher product benefits and lower bond yields.

In light of the strong second-quarter results, JPMorgan has revised its VNB forecasts for the fiscal years 2025 and 2026 upwards by 9% and 11%, respectively. While the outlook is positive, the firm also cautions that weaker margins in the participating segment or a slowdown in the enhancement of the product mix remain key risks to the insurer's performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.